HighTower Advisors’s Mustang Bio MBIO Stock Holding History

HighTower Advisors’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-394	Closed	-$5K	–	3964
2024 Q3	$5K	Hold	394	–	–	﹤0.01%	3589
2024 Q2	$9K	Hold	394	–	–	﹤0.01%	3456
2024 Q1	$21K	Buy	394 +6	+2%	+$381	﹤0.01%	3346
2023 Q4	$27K	Hold	388	–	–	﹤0.01%	3374
2023 Q3	$39K	Sell	388 -3	-0.8%	-$582	﹤0.01%	3254
2023 Q2	$122K	Buy	+391	New	+$98.2K	﹤0.01%	3033
2023 Q1	–	Sell	-390	Closed	-$115K	–	3564
2022 Q4	$115K	Buy	+390	New	+$133K	﹤0.01%	2921

Other funds holding MBIO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

HighTower Advisors's MBIO Position: Q4 2024 in Review

HighTower Advisors sold out of Mustang Bio (MBIO) in Q4 2024, closing a stake of 394 shares — an estimated $5K sold.

HighTower Advisors first reported a position in MBIO in Q4 2022 and held it in 7 quarters. The position peaked at $122K in Q2 2023. 30 funds tracked by Wall St. Rank hold MBIO as of Q4 2024.

HighTower Advisors reported no remaining Mustang Bio position as of Q4 2024 after selling out during the quarter.
HighTower Advisors sold 394 Mustang Bio shares in Q4 2024, an estimated $5K.
HighTower Advisors first reported a position in Mustang Bio in Q4 2022 and held it in 7 quarters.
HighTower Advisors's Mustang Bio position peaked at $122K in Q2 2023.
30 funds tracked by Wall St. Rank held Mustang Bio as of Q4 2024.

Based on HighTower Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.